Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17‐beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanisms
Christian A. Hudert, Leon A. Adams, Anna Alisi, Quentin M. Anstee, Annalisa Crudele, Laura G. Draijer, EU‐PNAFLD investigators, Samuel Furse, Jan G. Hengstler, Benjamin Jenkins, Kylie Karnebeek, Deirdre A. Kelly, Bart G. Koot, Albert Koulman, David Meierhofer, Phillip E. Melton, Trevor A. Mori, Stuart G. Snowden, Indra Mourik, Anita Vreugdenhil, Susanna Wiegand, Jake P.